BPC-157: A Plain-Language Overview of the Research

BPC-157 is one of the most-studied peptides in the preclinical research literature, and one of the most frequently asked-about compounds we carry. This article summarizes what published research has explored about BPC-157 — strictly as a reference for laboratory and research use. Nothing here is medical advice, and BPC-157 is not an approved drug or a product intended for human consumption.

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic peptide composed of 15 amino acids. Its sequence is derived from a partial fragment of a protein found in human gastric juice. In the research literature it is described as a stable gastric pentadecapeptide, and it has been used as a model compound in a large body of animal and in-vitro studies, most prominently by the research group of Sikiric and colleagues.^[1]

Because it is derived from a naturally occurring protein fragment, BPC-157 is often grouped with the “body protection” or cytoprotective peptides in research discussions. It is important to distinguish the published preclinical research — conducted in cell cultures and animal models — from any claim of a human clinical effect, which the current literature does not establish.

Areas explored in the research literature

Published studies — again, in cell and animal models — have investigated BPC-157 across several areas. The following reflects topics that appear in the scientific literature, not approved or intended uses:

• Tendon and ligament research. Studies have examined BPC-157's effect on tendon fibroblast outgrowth and cell migration in vitro, and on tendon-to-bone healing in rat models.^[2]
• Muscle and soft-tissue models. Animal-model work has looked at recovery in experimentally injured muscle tissue.^[1]
• Gastrointestinal research. Given its origin in gastric juice, much of the earliest work explored cytoprotection of the gastrointestinal lining in rodent models.^[1]
• Angiogenesis and the VEGFR2 pathway. Some research has explored a proposed mechanism involving blood-vessel formation and the VEGFR2 signaling pathway as a candidate explanation for the effects observed in these models.^[3]

What the research does not establish

It is just as important to be clear about the limits of the evidence. The overwhelming majority of BPC-157 research to date is preclinical — performed in vitro or in animals. Well-controlled human clinical trials establishing safety and efficacy are not part of the current published record. BPC-157 is not approved by the FDA, is not a dietary supplement, and is sold by Meridian strictly as a reference compound for laboratory and research use. Anyone evaluating the literature should weigh the preclinical nature of the evidence carefully.

Purity and characterization

For research purposes, the identity and purity of a peptide are what make results reproducible. Every lot of BPC-157 we supply ships with a Certificate of Analysis, and our compounds are third-party tested to 99%+ purity by HPLC with mass-spec verification of the sequence. When comparing sources for any research peptide, a current, lot-specific CoA — not a generic claim — is the baseline a serious lab should expect.

Frequently asked questions

Is BPC-157 a steroid?

No. BPC-157 is a peptide — a short chain of amino acids — not a steroid hormone. The two are entirely different classes of molecule.

What does “research use only” mean?

It means the compound is intended solely for in-vitro and laboratory research by qualified professionals, and is not intended for human or veterinary use, consumption, or any diagnostic or therapeutic purpose.

How should BPC-157 be stored?

In the research literature, lyophilized (freeze-dried) peptides are typically stored cold and protected from light; once reconstituted, they are generally kept refrigerated and used within a defined window. Follow your laboratory's own handling protocols.